At the European Congress on Obesity (ECO) in Malaga, digital health provider Yazen unveiled promising data from more than 30,000 patients across six European countries. The results highlight the effectiveness of Yazen’s digital obesity care model in achieving sustainable weight loss and high treatment adherence.
According to the data, patients using Yazen’s platform—available in Sweden, Norway, Denmark, the Netherlands, Germany, and Spain—lost an average of 16.4% of their body weight after 12 months. After 18 months, most patients maintained this weight loss. The program also saw treatment adherence rates much higher than those reported in traditional studies.
Yazen’s model combines modern weight-loss medications with guided lifestyle changes and psychological support, all delivered digitally. A significant portion of patients reached their target weight during the program and continued to follow healthy habits to sustain their progress. Women in the study lost more weight than men, with average losses of 17.6% compared to 13.4% for men over 18 months.
Beyond weight loss, patients experienced notable improvements in blood pressure, cholesterol, blood sugar, and liver function.
A second study analyzing data from nearly 26,000 patients found that 70% remained in treatment with Yazen after 12 months—substantially higher than retention rates seen in previous research.
A key factor in Yazen’s success is its personalized treatment approach. Unlike many healthcare providers who increase medication to the maximum dose regardless of individual response, Yazen adjusts doses based on patient needs. This approach minimizes side effects, reduces drug costs, and improves overall well-being.
Patients receive only the dose necessary to control hunger and improve their quality of life, leading to lower medication use than in many clinical trials. Still, 70% of patients stay in the program after a year, and 60% remain after two years. These long-term relationships with Yazen help patients maintain healthy habits even as medication doses are reduced.
“We see that patients who get the right mix of medication, lifestyle support, and digital care are far more likely to succeed,” said Yazen co-founder Martin Carlsson. “It’s time to rethink how we treat obesity and tailor care to individual needs.”
